Guido J Falcone1, Farid Radmanesh1, H Bart Brouwers1, Thomas W K Battey1, William J Devan1, Valerie Valant1, Miriam R Raffeld1, Lennox P Chitsike1, Alison M Ayres1, Kristin Schwab1, Joshua N Goldstein1, Anand Viswanathan1, Steven M Greenberg1, Magdy Selim1, James F Meschia1, Devin L Brown1, Bradford B Worrall1, Scott L Silliman1, David L Tirschwell1, Matthew L Flaherty1, Sharyl R Martini1, Ranjan Deka1, Alessandro Biffi1, Peter Kraft1, Daniel Woo1, Jonathan Rosand1, Christopher D Anderson2. 1. From the Center for Human Genetic Research (G.J.F., F.R., H.B.B., T.W.K.B., W.J.D., V.V., M.R.R., L.P.C., A.M.A., K.S., A.V., S.M.G., A.B., J.R., C.D.A.), J. Philip Kistler Stroke Research Center (G.J.F., F.R., H.B.B., T.W.K.B., W.J.D., V.V., M.R.R., A.B., J.R., C.D.A.), Division of Neurocritical Care and Emergency Neurology, Department of Neurology (G.J.F., F.R., H.B.B., T.W.K.B., W.J.D., M.R.R., A.B., J.R., C.D.A.), and Department of Emergency Medicine (J.N.G.), Massachusetts General Hospital, Boston; Program in Medical and Population Genetics (G.J.F., F.R., H.B.B., T.W.K.B., W.J.D., M.R.R., A.B., J.R., C.D.A.), Broad Institute, Cambridge, MA; Department of Epidemiology (G.J.F., P.K.), Harvard School of Public Health, Boston; Department of Neurology (M.S.), Beth Israel Deaconess Medical Center, Boston, MA; Department of Neurology (J.F.M.), Mayo Clinic, Jacksonville, FL; Stroke Program (D.L.B.), Department of Neurology, University of Michigan Health System, Ann Arbor; Departments of Neurology and Public Health Sciences (B.B.W.), University of Virginia Health System, Charlottesville; Department of Neurology (S.L.S.), University of Florida College of Medicine, Jacksonville; Stroke Center (D.L.T.), Harborview Medical Center, University of Washington, Seattle; and University of Cincinnati College of Medicine (M.L.F., S.R.M., R.D., D.W.), OH. 2. From the Center for Human Genetic Research (G.J.F., F.R., H.B.B., T.W.K.B., W.J.D., V.V., M.R.R., L.P.C., A.M.A., K.S., A.V., S.M.G., A.B., J.R., C.D.A.), J. Philip Kistler Stroke Research Center (G.J.F., F.R., H.B.B., T.W.K.B., W.J.D., V.V., M.R.R., A.B., J.R., C.D.A.), Division of Neurocritical Care and Emergency Neurology, Department of Neurology (G.J.F., F.R., H.B.B., T.W.K.B., W.J.D., M.R.R., A.B., J.R., C.D.A.), and Department of Emergency Medicine (J.N.G.), Massachusetts General Hospital, Boston; Program in Medical and Population Genetics (G.J.F., F.R., H.B.B., T.W.K.B., W.J.D., M.R.R., A.B., J.R., C.D.A.), Broad Institute, Cambridge, MA; Department of Epidemiology (G.J.F., P.K.), Harvard School of Public Health, Boston; Department of Neurology (M.S.), Beth Israel Deaconess Medical Center, Boston, MA; Department of Neurology (J.F.M.), Mayo Clinic, Jacksonville, FL; Stroke Program (D.L.B.), Department of Neurology, University of Michigan Health System, Ann Arbor; Departments of Neurology and Public Health Sciences (B.B.W.), University of Virginia Health System, Charlottesville; Department of Neurology (S.L.S.), University of Florida College of Medicine, Jacksonville; Stroke Center (D.L.T.), Harborview Medical Center, University of Washington, Seattle; and University of Cincinnati College of Medicine (M.L.F., S.R.M., R.D., D.W.), OH. cdanderson@partners.org.
Abstract
OBJECTIVE: We aimed to assess the effect of APOE ε variants on warfarin-related intracerebral hemorrhage (wICH), evaluated their predictive power, and tested for interaction with warfarin in causing wICH. METHODS: This was a prospective, 2-stage (discovery and replication), case-control study. wICH was classified as lobar or nonlobar based on the location of the hematoma. Controls were sampled from ambulatory clinics (discovery) and random digit dialing (replication). APOE ε variants were directly genotyped. A case-control design and logistic regression analysis were utilized to test for association between APOE ε and wICH. A case-only design and logistic regression analysis were utilized to test for interaction between APOE ε and warfarin. Receiver operating characteristic curves were implemented to evaluate predictive power. RESULTS: The discovery stage included 319 wICHs (44% lobar) and 355 controls. APOE ε2 was associated with lobar (odds ratio [OR] 2.46; p < 0.001) and nonlobar wICH (OR 1.67; p = 0.04), whereas ε4 was associated with lobar (OR 2.09; p < 0.001) but not nonlobar wICH (p = 0.35). The replication stage (63 wICHs and 1,030 controls) confirmed the association with ε2 (p = 0.03) and ε4 (p = 0.003) for lobar but not for nonlobar wICH (p > 0.20). Genotyping information on APOE ε variants significantly improved case/control discrimination of lobar wICH (C statistic 0.80). No statistical interaction between warfarin and APOE was found (p > 0.20). CONCLUSIONS: APOE ε variants constitute strong risk factors for lobar wICH. APOE exerts its effect independently of warfarin, although power limitations render this absence of interaction preliminary. Evaluation of the predictive ability of APOE in cohort studies is warranted.
OBJECTIVE: We aimed to assess the effect of APOE ε variants on warfarin-related intracerebral hemorrhage (wICH), evaluated their predictive power, and tested for interaction with warfarin in causing wICH. METHODS: This was a prospective, 2-stage (discovery and replication), case-control study. wICH was classified as lobar or nonlobar based on the location of the hematoma. Controls were sampled from ambulatory clinics (discovery) and random digit dialing (replication). APOE ε variants were directly genotyped. A case-control design and logistic regression analysis were utilized to test for association between APOE ε and wICH. A case-only design and logistic regression analysis were utilized to test for interaction between APOE ε and warfarin. Receiver operating characteristic curves were implemented to evaluate predictive power. RESULTS: The discovery stage included 319 wICHs (44% lobar) and 355 controls. APOE ε2 was associated with lobar (odds ratio [OR] 2.46; p < 0.001) and nonlobar wICH (OR 1.67; p = 0.04), whereas ε4 was associated with lobar (OR 2.09; p < 0.001) but not nonlobar wICH (p = 0.35). The replication stage (63 wICHs and 1,030 controls) confirmed the association with ε2 (p = 0.03) and ε4 (p = 0.003) for lobar but not for nonlobar wICH (p > 0.20). Genotyping information on APOE ε variants significantly improved case/control discrimination of lobar wICH (C statistic 0.80). No statistical interaction between warfarin and APOE was found (p > 0.20). CONCLUSIONS:APOE ε variants constitute strong risk factors for lobar wICH. APOE exerts its effect independently of warfarin, although power limitations render this absence of interaction preliminary. Evaluation of the predictive ability of APOE in cohort studies is warranted.
Authors: K R Bales; T Verina; D J Cummins; Y Du; R C Dodel; J Saura; C E Fishman; C A DeLong; P Piccardo; V Petegnief; B Ghetti; S M Paul Journal: Proc Natl Acad Sci U S A Date: 1999-12-21 Impact factor: 11.205
Authors: Daniel Woo; Laura R Sauerbeck; Brett M Kissela; Jane C Khoury; Jerzy P Szaflarski; James Gebel; Rakesh Shukla; Arthur M Pancioli; Edward C Jauch; Anil G Menon; Ranjan Deka; Janice A Carrozzella; Charles J Moomaw; Robert N Fontaine; Joseph P Broderick Journal: Stroke Date: 2002-05 Impact factor: 7.914
Authors: Elaine M Hylek; Alan S Go; Yuchiao Chang; Nancy G Jensvold; Lori E Henault; Joe V Selby; Daniel E Singer Journal: N Engl J Med Date: 2003-09-11 Impact factor: 91.245
Authors: Munir Pirmohamed; Girvan Burnside; Niclas Eriksson; Andrea L Jorgensen; Cheng Hock Toh; Toby Nicholson; Patrick Kesteven; Christina Christersson; Bengt Wahlström; Christina Stafberg; J Eunice Zhang; Julian B Leathart; Hugo Kohnke; Anke H Maitland-van der Zee; Paula R Williamson; Ann K Daly; Peter Avery; Farhad Kamali; Mia Wadelius Journal: N Engl J Med Date: 2013-11-19 Impact factor: 91.245
Authors: Thor D Stein; Philip H Montenigro; Victor E Alvarez; Weiming Xia; John F Crary; Yorghos Tripodis; Daniel H Daneshvar; Jesse Mez; Todd Solomon; Gaoyuan Meng; Caroline A Kubilus; Kerry A Cormier; Steven Meng; Katharine Babcock; Patrick Kiernan; Lauren Murphy; Christopher J Nowinski; Brett Martin; Diane Dixon; Robert A Stern; Robert C Cantu; Neil W Kowall; Ann C McKee Journal: Acta Neuropathol Date: 2015-05-06 Impact factor: 17.088
Authors: Alvin S Das; Elif Gökçal; Robert W Regenhardt; Andrew D Warren; Alessandro Biffi; Joshua N Goldstein; W Taylor Kimberly; Anand Viswanathan; Lee H Schwamm; Jonathan Rosand; Steven M Greenberg; M Edip Gurol Journal: J Neurol Date: 2022-08-23 Impact factor: 6.682
Authors: Alessandro Biffi; Sebastian Urday; Patryk Kubiszewski; Lee Gilkerson; Padmini Sekar; Axana Rodriguez-Torres; Margaret Bettin; Andreas Charidimou; Marco Pasi; Christina Kourkoulis; Kristin Schwab; Zora DiPucchio; Tyler Behymer; Jennifer Osborne; Misty Morgan; Charles J Moomaw; Michael L James; Steven M Greenberg; Anand Viswanathan; M Edip Gurol; Bradford B Worrall; Fernando D Testai; Jacob L McCauley; Guido J Falcone; Carl D Langefeld; Christopher D Anderson; Hooman Kamel; Daniel Woo; Kevin N Sheth; Jonathan Rosand Journal: Stroke Date: 2020-06-10 Impact factor: 10.170